A	FDA	C54450	Patient Problem Codes FDA CDRH	C3720	3264	ANAPLASTIC LARGE CELL LYMPHOMA	ALCL		A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)	C3208	3263	LYMPHOMA
A	FDA	C54450	Patient Problem Codes FDA CDRH	C9305	3262	CANCER	MALIGNANT NEOPLASM		A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.	C54027	2688	PATIENT PROBLEM/MEDICAL PROBLEM
A	FDA	C54450	Patient Problem Codes FDA CDRH	C3208	3263	LYMPHOMA			A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.	C9305	3262	CANCER
C	FDA	C54450	Patient Problem Codes FDA CDRH	C4872	1759	CANCER, BREAST	BREAST CANCER		A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.	C9305	3262	CANCER
C	FDA	C54450	Patient Problem Codes FDA CDRH	C50477	1760	CANCER, OTHER				C9305	3262	CANCER
C	FDA	C54450	Patient Problem Codes FDA CDRH	C50461	2491	AORTIC DISSECTION	DISSECTION, AORTIC		A progressive tear in the aorta characterized by a separation of the media layer from the outer-most layer.	C54027	2688	PATIENT PROBLEM/MEDICAL PROBLEM